Company Profile
Established in Beijing in September 1995, Beijing Beier Bioengineering Co., Ltd. is a high-tech enterprise in China specializing in the development and production of in vitro diagnostic reagents.
Technological innovation has always been the first driving force for the company's continuous development. After more than 20 years of independent research and development, Beier has built a multi-type and multi-project integration technology platforms, including magnetic particle chemiluminescence diagnostic reagent, ELISA diagnostic reagent platform, colloidal gold POCT rapid diagnostic reagent, PCR molecular diagnostic reagent, biochemical diagnostic reagent, and equipment manufacturing. If has formed a complete product line covering respiratory pathogens, prenatal and postnatal care, hepatitis, Epstein-Barr virus, autoantibodies, tumor markers, thyroid function, liver fibrosis, hypertension, and other fields.
Our Advantage
Since its establishment, the sales revenue has continued to grow, and it has gradually become one of the first-class domestic in vitro diagnostic product companies in China.
Cooperative Relationship
As one of the companies with the most complete range of immunodiagnostic products in the industry, Beier has reached a long-term cooperative relationship with more than 10,000 hospitals and more than 2,000 partners in and outside China.
High Market Share
Among them, diagnostic reagents for respiratory pathogens, Epstein-Barr virus and prenatal and postnatal care are the first products approved for marketing in China, ranking among the top three in domestic market share and have broken through the monopoly position of imported products in China.
Develop Well
Beier takes human health as its own mission and focuses on exploring new areas of detection. At present, Beier has formed a pattern of group development and diversified development of product platforms.
Company History
-
- In 1995, establishment as a high-tech enterprise.
1995 -
- In 1998, "Human Chorionic Gonadotropin test kit (Colloidal Gold)" was approved by the Ministry of Health.
1998 -
- In 1999, undertook the National 863 Program "Research on Specific Gene Diagnostic Reagents for Pathogenic Microorganisms" to develop the Helicobacter pylori antibody ELISA kit.
1999 -
- In 2001, the first company in China to obtain the registration of "Anti-Helicobacter pylori antibody ELISA kit".
2001 -
- In 2005, GMP certified.
2005 -
- In 2006, the first company in China to obtain the registration for the "Human Cytomegalovirus IgM Antibody ELISA Kit ".
2006 -
- In 2007, the first company in China to obtain the registration for the "EB VCA antibody (IgA) ELISA kit".
2007 -
- In 2008, the first company in China to obtain the registration of "10 products of TORCH ELISA and 4 items of TORCH-IgM Rapid test".
2008 -
- In 2009, the first company in China to obtain the registration of the " Test Kit for Hepatitis D Virus".
2009 -
- In 2010, the first company in China to obtain the registration of "Enterovirus 71 IgM / IgG ELISA kit". Second-time GMP certified.
2010 -
- In 2011, the "Giant Cell Recombinant Antigen" project won the third prize of Science and Technology Progress Award.
2011 -
- In 2012, the first company to obtain the registration of the "EB virus series test kit (Enzyme-linked Immunoassay)" for the diagnosis of infectious monocyte dysentery.
2012 -
- In 2013, the first company to obtain the registration of the Coxsackie Group B virus IgM / IgG ELISA kit for the detection of viral myocarditis.
2013 -
- In 2014, undertook the development of respiratory pathogen detection kits in the national twelfth five-year key research project "AIDS and Major Infectious Diseases Project". It was the first company in China to obtain the registration of 12 respiratory pathogens IgM / IgG antibody test kits.
2014 -
- In 2015, the first company in China to obtain the registration of the "streptococcus pneumoniae antigen test kit" and completed the third-time GMP certification.
2015 -
- In 2016, "EV71 virus IgM test kit" won the third prize of Beijing Science and Technology Progress. "Research and development and application of pathogenic microorganism series diagnostic reagents and technologies" won the first prize of Jiangsu Pharmaceutical Science and Technology Progress. Passed the ISO13485 certification assessment.
2016 -
- •In 2017, undertook the development of diagnostic reagents for sudden acute infectious diseases in the National 13th Five-Year Key Project "Prevention and Control of Major Infectious Diseases such as AIDS and Viral Hepatitis".
2017 -
- In 2018, obtained TORCH 10 (Magneto particle Chemiluminescence) product registration.
2018 -
- •In 2019, the first domestic company to obtain the registration of respiratory pathogens (magnetic particle chemiluminescence). •In 2019, obtained the registration of EB virus (magnetic particle chemiluminescence) series products.
2019 -
- In 2020, undertook the Beijing Municipal Science and Technology Commission's emergency project "R & D of New Coronavirus (2019-nCoV) Antibody Rapid Test Cassette". The COVID-19 Antigen Rapid Test obtained the CE registration, which meets the EU access qualification. Obtained the registration of quality control products for eugenic 10 items.
2020 -
- In 2021, the first company in China to obtain registration for 9 items of IgM antibody quality control products for respiratory infection pathogens. COVID-19 Antigen Rapid Test obtained the CE certificate for self-testing from PCBC.
2021 -
- •In 2022, COVID-19 Antigen Rapid Test entered into the EU Common list category A.
2022
